Shares of Valeant Pharmaceuticals International Inc. climbed Wednesday after the Canadian drugmaker said it expects market share gains in most of its businesses and that its third-quarter revenue will top forecasts.
The drugmaker also said it expects 10 percent growth from the established business of its contact lens maker Bausch + Lomb, a target of criticism in Valeant’s on-going takeover battle with Botox-maker Allergan Inc.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.